Home·Explore by biomarker·deficient mismatch repair (dMMR) proteins

deficient mismatch repair (dMMR) proteins

Biomarker

dMMR status reflects loss of DNA mismatch repair function. dMMR tumors are eligible for immune checkpoint inhibitor therapies.

Approvals
5
Indications
3
Therapies
5
Mapped tests
2

Where this biomarker is used

Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.

Indication-specific approvals

Approvals where deficient mismatch repair (dMMR) proteins is defined directly in the indication labeling.

IndicationBiomarker criteriaTherapies
Colorectal Cancer (CRC)
Solid Tumor · Colorectal
  • MLH1, PMS2, MSH2 and MSH6
OPDIVOOPDIVO + YERVOY
Endometrial Carcinoma (EC)
Solid Tumor · Endometrium
  • MLH1, PMS2, MSH2 and MSH6
IMFINZIJEMPERLI
Tumor-agnostic approvals

Approvals defined at the solid tumor level where deficient mismatch repair (dMMR) proteins is part of the eligibility criteria.

LevelBiomarker criteriaTherapies
Solid Tumors
  • MLH1, PMS2, MSH2 and MSH6
KEYTRUDAJEMPERLI

Tests that measure this biomarker

These assays report deficient mismatch repair (dMMR) proteins as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.

Test
MMR IHC Panel pharmDx
Dako Omnis
Method
IHC
Specimen
Tissue (FFPE)

Reports deficient mismatch repair (dMMR) proteins as part of its biomarker panel.

1 approvalView test profile →
Test
Ventana MMR RxDx Panel
Ventana Medical Systems, Inc.
Method
IHC
Specimen
Tissue (FFPE)

Reports deficient mismatch repair (dMMR) proteins as part of its biomarker panel.

4 approvalsView test profile →
This view is scoped to deficient mismatch repair (dMMR) proteins. You can also see how it compares with other biomarkers and indications on the Know Your Companions™ map.